Search Results for: covid-19
Articles
Vaccitech Doses First Patients in Phase 2b Clinical Trial of VTP-300 Immunotherapeutic Candidate October 31, 2022
Vaccitech plc recently announced the dosing of the first patients in HBV003, a Phase 2b clinical trial designed to further...FORMULATION FORUM - Lipid Nanoparticles: Tackling Solubility Challenges With Lipid-Based Technologies for Oral & Injectable Formulations October 10, 2022
Jim Huang, PhD, and Shaukat Ali, PhD, believe as more hydrophobic or brick dust and/or lipophilic or waxy molecules come out of discovery, amorphous solid dispersions (ASDs) and lipid based self-emulsifying microemulsions, nanoemulsions, liposomes, and nanoparticles are ideal for oral and injectable formulations.
Monopar Announces Completion of Phase 2b Enrollment & Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis October 5, 2022
Monopar Therapeutics Inc. recently announced an update on its actively enrolling Validive Phase 2b/3 VOICE clinical trial for the prevention...RIGImmune Announces Acquisition of Antiviral Company Subintro September 16, 2022
RIGImmune Inc. recently announced the acquisition of Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics...Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine September 13, 2022
Vaxxinity, Inc. recently announced the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine...BD Launches Next-Generation Prefillable Vaccine Syringe September 13, 2022
BD (Becton, Dickinson and Company) recently introduced a next-generation glass prefillable syringe (PFS) that sets a new standard in performance for vaccine PFS with new and….
Avalo Advances BTLA Agonist Fusion Protein to IND-Enabling Stage September 6, 2022
Avalo Therapeutics, Inc. recently announced its human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein, AVTX-008, has now entered...Qureight Announces World’s First Digital Biomarker for Lung Fibrosis September 1, 2022
For the first time, artificial intelligence (AI) using convolutional neural networks has been used to analyse trial data involving the lung disease idiopathic pulmonary fibrosis (IPF). The technology picked up….
SPECIAL FEATURE - Injection Devices: Three Trends Influencing Development & Delivery September 1, 2022
Contributor Cindy H. Dubin showcases in this annual feature how various innovative device manufacturers are addressing the current trends in their injection designs.
EXECUTIVE INTERVIEW - Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics August 31, 2022
Bill Hartzel, Senior Vice President and Head of CDMO Business, discusses the company’s plans for current and future CDMO operations and client partnership opportunities.
LIVE BIOTHERAPEUTIC PRODUCTS - Not All Microbiome Approaches Are Created Equal August 31, 2022
Duncan Peyton says in comparison with other therapeutic classes, such as antibodies or gene therapy, the progress that has been made with LBPs to date has been rapid, and for the field to maintain this rate of progress and to establish LBPs as a mainstay in the treatment of patients across a variety of diseases, a number of key questions need to be addressed.
2022 Analytical Testing eBook – Service Providers Offer Innovation August 23, 2022
Learn more about the technologies from Alcami, Associates of Cape Cod, Stevanato Group, and West in this exclusive 2022 Drug Development & Delivery Analytical Testing e-book.
Gerresheimer Invests Up to $94 Million in US Production Facility August 15, 2022
Gerresheimer AG recently announced investments to rapidly expand its manufacturing, supply, and logistics capability for glass vials in the US. The project will be supported by the Biomedical Advanced Research….
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership With Ginkgo Bioworks August 11, 2022
Synlogic, Inc. recently announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks The new...Saama Collaborates With Merck to Build Machine Learning-Powered Clinical Data Layer to Strengthen Clinical Development Capabilities August 10, 2022
Saama Technologies, LLC recently announced a multi-year agreement with Merck to build and operationalize a new clinical data layer leveraging Saama’s Life Science Analytics Cloud (LSAC) to….
Valneva & Pfizer Initiate Phase 3 Study of Lyme Disease Vaccine Candidate August 9, 2022
Valneva SE and Pfizer recently announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and….
Rigel Pharmaceuticals & Forma Therapeutics Announce Licensing Agreement for Novel Mutant IDH1 Inhibitor August 3, 2022
Rigel Pharmaceuticals, Inc. and Forma Therapeutics, Inc. recently announced they have entered into an exclusive, worldwide license agreement to develop, manufacture, and commercialize….
New Lipid Facility at Evonik’s Site in Hanau to Produce Clinical & Launch Quantities of Lipids for Innovative Medicines August 2, 2022
Evonik is building a new cGMP facility to manufacture lipids for clinical development and launch of innovative medicines. The new cGMP lipid launch facility is located in….
SCHOTT Establishes Stand-Alone Company for its Pharma Business to Promote Further Growth August 1, 2022
SCHOTT has legally established a stand-alone company for its pharma business to advance its growth strategy. As a pioneer in pharma drug containment and system solutions, the international technology….
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients With Primary Biliary Cholangitis August 1, 2022
CymaBay Therapeutics, Inc. recently announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary….
